Innoviva (INVA) FCF Margin Growth (5y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -785,446.00 |
| Sep 30, 2025 | 4,701.00 |
| Jun 30, 2025 | -5,713.00 |
| Mar 31, 2025 | -3,853.00 |
| Sep 30, 2024 | 5,703.00 |
| Jun 30, 2024 | -4,437.00 |
| Mar 31, 2024 | 369,618.00 |
| Sep 30, 2023 | 6,244.00 |
| Jun 30, 2023 | 381,902.00 |
| Mar 31, 2023 | 312,720.00 |
| Sep 30, 2022 | 1.47 Mn |
| Jun 30, 2022 | 415,794.00 |
| Mar 31, 2022 | 786,777.00 |
| Sep 30, 2021 | 21,135.00 |
| Jun 30, 2021 | 720,600.00 |
| Mar 31, 2021 | 785,997.00 |
| Dec 31, 2020 | 1.69 Mn |
| Sep 30, 2020 | 6,448.00 |
| Jun 30, 2020 | 8,067.00 |
| Mar 31, 2020 | 11,690.00 |
| Dec 31, 2019 | 15,320.00 |
| Sep 30, 2019 | 219,651.00 |
| Jun 30, 2019 | 579,916.00 |
| Mar 31, 2019 | 683,853.00 |
| Dec 31, 2018 | 286,358.00 |
| Sep 30, 2018 | 1.01 Mn |
| Jun 30, 2018 | 139,155.00 |
| Mar 31, 2018 | 254,393.00 |
| Dec 31, 2017 | 4,913.00 |
| Sep 30, 2017 | 205,668.00 |
| Jun 30, 2017 | 673,598.00 |
| Mar 31, 2017 | 10,229.00 |
| Dec 31, 2016 | 53,805.00 |
| Sep 30, 2016 | 35,987.00 |
| Jun 30, 2016 | 33,794.00 |
| Mar 31, 2016 | 46,076.00 |